Question 1

What is Hizentra?

Accepted Answer

Hizentra is a highly purified form of human immunoglobulin G (IgG) derived from human plasma. It contains a broad spectrum of antibodies that help the body recognize and neutralize various bacteria and viruses.

By replacing missing or deficient antibodies, this therapy supports the immune system's ability to defend against pathogens.

Question 2

What is Hizentra used for?

Accepted Answer

Hizentra is used to treat primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy .

Question 3

How does Hizentra work?

Accepted Answer

Antibody Replacement

Hizentra is a solution made of human antibodies called immunoglobulin G (IgG). These are proteins that the immune system typically uses to find and destroy germs like bacteria and viruses. For people with primary immunodeficiency, the body does not produce enough of these antibodies. Hizentra works by replacing the missing IgG, which helps the body defend itself against infections.

Immune Regulation

In the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), the immune system mistakenly attacks the nerves. While the exact way Hizentra works for this condition is not fully understood, it is believed to help regulate the immune system. By introducing healthy antibodies, the medication may help prevent the immune system from attacking the protective covering of the nerves.

Subcutaneous Delivery

The medication is injected into the fatty tissue directly under the skin. It is then slowly absorbed into the bloodstream. This method of delivery allows the antibodies to enter the system gradually, which helps maintain a steady level of protection in the body between doses.

Question 4

What are the active ingredients in Hizentra?

Accepted Answer

The active ingredient in Hizentra is immunoglobulin G .

Question 5

What are the side effects of Hizentra?

Accepted Answer

Common side effects of Hizentra may include:

injection site reactions

headache

fatigue

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Hizentra?

Accepted Answer

Hizentra belongs to the immunoglobulin drug class.

Question 7

What is the dosage of Hizentra and how do I take it?

Accepted Answer

How Hizentra is Administered

Hizentra is for subcutaneous use only, meaning it is injected into the fatty tissue just under the skin. It should not be injected into a vein. Patients or caregivers can often be trained to administer the medication at home using an infusion pump or, in some cases, a manual push method with a syringe.

Injection Sites

Common areas for injection include the abdomen, thighs, upper arms, or the sides of the upper legs or hips. If you are using multiple injection sites at once, they should be at least two inches apart. It is important to rotate the injection sites with each treatment to help prevent skin irritation.

Preparation and Handling

Temperature: If the medication is refrigerated, allow it to reach room temperature before use. Do not use external heat sources like a microwave to warm it.

Inspection: Check the liquid for particles or discoloration before use. The solution should be clear and pale yellow or light brown. Do not use it if it is cloudy or contains bits of material.

Mixing: Do not shake the vial, as this can damage the protein in the medicine.

Missed Doses

If you miss a scheduled dose of Hizentra, contact your healthcare provider or pharmacist for instructions on when to take your next dose. Do not use extra medicine to make up for a missed dose.

Question 8

Is Hizentra safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate and well-controlled studies of Hizentra in pregnant women. It is unknown whether the medication can cause harm to a developing fetus or affect reproductive capacity. Animal reproduction studies have not been conducted with this drug.

Immune globulins are known to cross the placenta, especially during the third trimester. Because of the lack of specific data, Hizentra should only be given to a pregnant woman if it is clearly needed and recommended by a doctor.

Breastfeeding

It is not known if Hizentra is excreted in human breast milk. Because many medications can be passed through milk, caution should be used when administering Hizentra to someone who is nursing. Patients should talk to their healthcare provider about the potential risks and benefits of breastfeeding while using this medication.

Question 9

What forms and strengths does Hizentra come in?

Accepted Answer

Available Forms

Hizentra is a sterile liquid solution intended for subcutaneous infusion. It is provided in ready-to-use formats to be administered under the skin.

The medication is available in the following forms:

Single-use vials: These containers are intended for one-time use and do not contain preservatives.

Prefilled syringes: These are ready-to-use syringes designed for subcutaneous administration.

The solution is clear and may range in color from colorless to pale yellow or light brown. Because it is a biological product, it must be inspected for particles or discoloration before use.

Question 10

What is the FDA approval status of Hizentra?

Accepted Answer

FDA Approval Status

Hizentra (Immune Globulin Subcutaneous [Human], 20% Liquid) was first approved by the U.S. Food and Drug Administration (FDA) in March 2010. It was the first 20% subcutaneous immunoglobulin (SCIg) therapy available in the United States.

Approved Indications

The FDA has approved Hizentra for the following uses:

Primary Immunodeficiency (PI): For the treatment of adults and pediatric patients 2 years of age and older.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): For the treatment of adults as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Boxed Warning

Hizentra contains a boxed warning from the FDA regarding the risk of thrombosis (blood clots). Thrombosis may occur even in the absence of known risk factors. For patients at risk, the drug should be administered at the minimum dose and infusion rate practicable. Patients should be well hydrated before administration.

Regulatory History and Safety

Since its initial approval for primary immunodeficiency, the FDA expanded Hizentra's indications in 2018 to include the treatment of CIDP. The product is subject to ongoing regulatory oversight to ensure manufacturing standards and safety profiles are maintained. Healthcare providers are encouraged to report any serious adverse events to the FDA MedWatch program.

Question 11

What should I know about Hizentra and cost?

Accepted Answer

Insurance Coverage

Most insurance plans, including Medicare and Medicaid, provide coverage for Hizentra. However, because it is a specialty medication, insurance companies often require prior authorization. This process involves your healthcare provider submitting documentation to prove the medical necessity of the treatment before the insurer agrees to cover the cost.

Financial Assistance Programs

There are several options available to help manage the expenses associated with Hizentra:

Co-pay Relief: Eligible patients with private or commercial insurance may qualify for a co-pay assistance program provided by the manufacturer to reduce out-of-pocket costs.

Patient Assistance: For those without insurance or with limited coverage, patient assistance programs may provide the medication at a lower cost or for free, depending on financial eligibility.

Support Programs: Specialized support services can assist patients in understanding their benefits and finding financial resources.

The final cost is also determined by the specific dosage and frequency of administration, which are tailored to the individual's weight and medical condition.

Hizentra

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?